Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.

Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY.

Int J Artif Organs. 2013 Mar;36(3):208-16. doi: 10.5301/IJAO.5000191. Epub 2013 Feb 13.

PMID:
23404639
2.

Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.

Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T.

Int J Artif Organs. 2011 Jul;34(7):571-6. doi: 10.5301/IJAO.2011.8535.

PMID:
21786254
3.

Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.

Lee YK, Lee HW, Choi KH, Kim BS.

PLoS One. 2014 Oct 10;9(10):e108737. doi: 10.1371/journal.pone.0108737. eCollection 2014.

4.

Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA.

Intensive Care Med. 2007 Sep;33(9):1563-70. Epub 2007 Jun 27.

PMID:
17594074
5.

The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.

Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE.

Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17.

PMID:
22251267
7.

Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.

Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A.

J Nephrol. 2003 Jul-Aug;16(4):566-71.

PMID:
14696760
8.

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.

Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW.

Am J Kidney Dis. 2012 Jun;59(6):810-8. doi: 10.1053/j.ajkd.2011.11.030. Epub 2012 Jan 5. Review.

PMID:
22226564
9.

Anticoagulation in acute blood purification for acute renal failure in critical care.

Shinoda T.

Contrib Nephrol. 2010;166:119-25. doi: 10.1159/000314861. Epub 2010 May 7. Review.

PMID:
20472999
10.
11.

Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.

Kikura M, Tanaka K, Hiraiwa T, Tanaka K.

J Cardiothorac Vasc Anesth. 2012 Apr;26(2):239-44. doi: 10.1053/j.jvca.2011.09.002. Epub 2011 Oct 22.

PMID:
22019206
12.

Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure.

Chua HR, Baldwin I, Bailey M, Subramaniam A, Bellomo R.

J Crit Care. 2012 Dec;27(6):744.e7-15. doi: 10.1016/j.jcrc.2012.08.016. Epub 2012 Oct 24.

PMID:
23102533
13.

Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial.

Brain MJ, Roodenburg OS, Adams N, McCracken P, Hockings L, Musgrave S, Butt W, Scheinkestel C.

Crit Care Resusc. 2014 Jun;16(2):131-7.

PMID:
24888284
14.

Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.

Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, Lee SH.

J Korean Med Sci. 2011 Jul;26(7):945-50. doi: 10.3346/jkms.2011.26.7.945. Epub 2011 Jun 20.

15.

Anticoagulation for continuous renal replacement therapy.

Tolwani AJ, Wille KM.

Semin Dial. 2009 Mar-Apr;22(2):141-5. doi: 10.1111/j.1525-139X.2008.00545.x. Review.

PMID:
19426417
16.

Single-dose application of antithrombin as a potential alternative anticoagulant during continuous renal replacement therapy in critically ill patients with advanced liver cirrhosis: a retrospective data analysis.

Brunner R, Leiss W, Madl C, Druml W, Holzinger U.

Anesth Analg. 2013 Mar;116(3):527-32. doi: 10.1213/ANE.0b013e31827ced39. Epub 2013 Feb 11.

PMID:
23400980
17.

Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.

Kalb R, Kram R, Morgera S, Slowinski T, Kindgen-Milles D.

Ther Apher Dial. 2013 Apr;17(2):202-12. doi: 10.1111/j.1744-9987.2012.01101.x. Epub 2012 Aug 29.

PMID:
23551677
18.

Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).

Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL.

Nephrol Dial Transplant. 2005 Jul;20(7):1416-21. Epub 2005 Apr 26.

19.

Nafamostat mesilate is not appropriate as an anticoagulant during continuous renal replacement therapy in dogs.

Shimokawa Miyama T, Yoshioka C, Minami K, Okawa T, Hiraoka H, Itamoto K, Mizuno T, Okuda M.

J Vet Med Sci. 2010 Mar;72(3):363-7. Epub 2009 Dec 4.

20.

A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults.

Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R.

Crit Care Med. 2015 Aug;43(8):1622-9. doi: 10.1097/CCM.0000000000001004.

PMID:
25853591
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk